Minnelide Inhibits ...
 
Notifications
Clear all

Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants.


johan
(@j)
Joined: 4 years ago
Posts: 887
Topic starter  

"Our study showed that treatment with triptolide induced apoptotic cell death in CRPC cells. Triptolide treatment inhibited AR transcriptional activity and decreased the expression of AR and its splice variants both at the mRNA and the protein level. Our studies show that triptolide inhibits nuclear translocation of Sp1, resulting in its decreased transcriptional activity leading to downregulation of AR and its splice variants in prostate cancer cells. In vivo, Minnelide (0.21 mg/kg) regressed subcutaneous tumors derived from CRPC 22RV1 at our study endpoint. Our animal studies further confirmed that Minnelide was more efficacious than the standard of care therapies, Docetaxel and Enzalutamide."


Shanti liked
Quote
johan
(@j)
Joined: 4 years ago
Posts: 887
Topic starter  

I forgot the post the link to the study. Here it is:

https://www.ncbi.nlm.nih.gov/pubmed/28144973


Shanti and Manuone liked
ReplyQuote
Share: